MM-111   Click here for help

GtoPdb Ligand ID: 8931

Synonyms: 
Compound class: Antibody
Comment: MM-111 is a bispecific antibody fusion protein that co-targets the epidermal growth factor family receptor tyrosine kinases, ERBB2 and ERBB3 [1].
Annotated peptide sequences for this construct are available from its IMGT/mAb-DB record.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
In August 2013, Merrimack Pharmaceutical announced that they had been granted FDA orphan drug status for MM-111 for the treatment of advanced gastric and esophageal cancers. MM-111 reached Phase 2 clinical trial in HER2-positive gastric cancer. However, in early 2015, the maufacturer terminated development due to poor responses, including inferior progression-free survival in the experimental arm of the trial in metastatic HER2-positive gastric cancer patients.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
MM-111 forms a complex with ErbB2 and ErbB3, which effectively inhibits ErbB3 signaling. This action underlies the antibody's antitumor activity in preclinical models [1].